Definitive Contract 75N93020C00019
Award Date
7/1/20
Potential Completion Date
10/13/26
Potential Value
$7.6M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Microbiotix, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Worcester, MA 01605, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award to Microbiotix, Inc., a clinical-stage biopharmaceutical company, was issued by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), under a Broad Agency Announcement (BAA). The $14,195,727 cost-plus-fixed-fee contract supports the development of small molecule pan-filovirus entry inhibitors through lead optimization, selection of a preclinical candidate, and IND-enabling preclinical studies. The...
This $18,274,778 definitive contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to AN2 Therapeutics, Inc. The contract supports the development of epetraborole as a novel therapeutic for melioidosis and additional antimicrobial resistant bacterial biothreat pathogens. This award was issued under a Broad Agency Announcement (BAA) that also sought proposals for advanced vaccine and diagnostic development against biodefense and emerging...
This is a $3,624,974 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Trius Therapeutics, Inc. for the "DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has a period of performance from September 16, 2013 to September 15, 2015, with a ceiling value of $845,876.06. There is no set-aside for this award....
This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Pharmacology Discovery Services Taiwan, Ltd., a for-profit Taiwanese company that provides preclinical disease modeling services. The $506,429.00 delivery order is for the development and testing of murine (mouse) models of lung infections caused by antibiotic-resistant Pseudomonas aeruginosa bacteria, to support...
This is a $30,704,925.57 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services, to Achaogen, Inc., a for-profit organization. The contract was awarded on September 1, 2008, with a period of performance through August 27, 2016, and was not set aside for any specific business type. The contract was awarded under a Broad Agency Announcement (BAA) solicitation, BAA...
This is a $4,590,862.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Sorrento Therapeutics, Inc., a small disadvantaged business. The contract is for the "DEVELOPMENT OF IN VITRO FOR BIODEFENSE, ANTIMICROBIAL RESISTANT (AMR) INFECTIONS AND EMERGING INFECTIOUS DISEASES", which was a Broad Agency Announcement (BAA) research area. The contract has a period of performance through May 2, 2025...
This is a $140,973,858.69 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the Department of Health and Human Services, to the American Type Culture Collection (ATCC) as the prime contractor. The contract is for the Microbiology and Infectious Diseases Biological Research Repository (MID-BRR), which serves as a centralized repository for critical microbial strains, biospecimens, and reagents to support infectious disease research....
This federal contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to The Global Alliance For TB Drug Development Inc., a non-profit organization. The $9,851,406.00 cost-no-fee contract is for the development of a novel modulator targeting proteostasis for the treatment of M. tuberculosis, with a completion date of April 30, 2028. The contract was awarded under NIAID's Broad...
This is a new contract award by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services (HHS), to Trius Therapeutics, Inc., a for-profit organization. The contract, awarded under Broad Agency Announcement NIH-NIAID-DMID-08-20, is a definitive, cost-plus-fixed-fee contract with a ceiling value of $25,641,873.40 and an ultimate completion date of August 31, 2013. The contract does not have a set-aside designation. As NIAID is...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $31,725,938.61 cost-plus-fixed-fee contract to Revagenix Inc. to select a novel small molecule antibiotic for clinical development and advance it through IND filing and Phase 1 clinical studies. This contract was not set aside and has an ultimate completion date of August 31, 2026. The contract originated from a NIAID Broad Agency Announcement seeking proposals to develop medical countermeasures to mitigate and/or...